Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million
Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.
How this was made
The 30-second read
Why it matters
The Q2 2026 earnings release combines a large YoY revenue jump, improved adjusted loss, and a liquidity runway extension via non-dilutive royalty financing, which can reduce near-term financing overhang. The key trading question is whether commercial AVMAPKI CO-PACK net product revenue can sustain growth without milestone support while expenses continue to rise.
Market read
Traders are likely to reprice near-term risk after the revenue and adjusted-loss beat and the disclosed financing runway into 2H 2027, but will watch for durability of product revenue versus milestone effects.
What to watch
R&D and operating expenses rose sharply (R&D +67% YoY), and the company issued no numerical revenue or EPS guidance, increasing uncertainty around the next quarters’ trajectory.
Background
Verastem Oncology is a clinical-development and commercial-stage oncology biopharma with an FDA-accelerated, previously treated KRAS-mutated LGSOC therapy (AVMAPKI CO-PACK) and a pipeline led by VS-7375.
Ticker impact
Verastem reported Q2 2026 revenue of $40.1M, driven by AVMAPKI CO-PACK sales and a COPIKTRA milestone, with after-hours shares up ~9%.
Bullish bias for the next session(s) given the after-hours reaction, with follow-through dependent on whether commercial sales sustain beyond milestone effects.
The article discloses a same-day earnings print (revenue and adjusted loss) and a liquidity extension via Oberland royalty financing, both of which can re-rate near-term risk. However, it provides no forward revenue/EPS guidance and highlights rising operating expenses and trial expansion, limiting conviction.
Market effects
Supports sentiment for small-cap oncology biopharma names with commercial launches plus milestone-driven revenue, but does not change sector fundamentals broadly.
Limited, primarily affects US small-cap biotech risk appetite rather than broader regional flows.
Low, as the disclosed catalysts are company-specific (commercial sales, milestone, and financing).
Counterpoint
The revenue surge is heavily influenced by a non-recurring $15M COPIKTRA milestone, so the beat may not translate into durable run-rate growth.
Key entities
- companyVerastem Oncology
Nasdaq-listed oncology biopharma reporting Q2 2026 results and updated pipeline/capital runway commentary.
- productAVMAPKI FAKZYNJA CO-PACK
FDA-approved therapy whose net product revenue drove Q2 2026 commercial results.
- productCOPIKTRA
License and related-asset revenue included a $15.0M milestone contribution in Q2 2026.
- financing_partnerOberland Capital
Agreed to provide up to $75.0M in non-dilutive royalty financing, including a closing tranche and a sales-conditions tranche.
- pipeline_assetVS-7375
Clinical-stage KRAS G12D inhibitor with updated data and trial enrollment milestones referenced for Oct 2026 and 2027.
